Cim, LLC Harmony Biosciences Holdings, Inc. Transaction History

Cim, LLC

$685 Million
Q4 2024

A detailed history of Cim, LLC transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Cim, LLC holds 13,396 shares of HRMY stock, worth $472,610. This represents 0.07% of its overall portfolio holdings.

Number of Shares

13,396

Previous 13,304 0.69%

Holding current value

$472,610

Previous $531,000 13.37%

% of portfolio

0.07%

Previous 0.08%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Mar 03, 2025	BUY	$31.86 - $41.49 $2,931 - $3,817	92 Added 0.69%	13,396 $460,000
Q3 2024 Jan 16, 2025	SELL	$30.0 - $39.95 $6,510 - $8,669	-217 Reduced 1.6%	13,304 $531,000
Q2 2024 Sep 06, 2024	BUY	$28.81 - $33.01 $49,121 - $56,282	1,705 Added 14.43%	13,521 $407,000
Q1 2024 May 20, 2024	BUY	$29.93 - $35.06 $3,501 - $4,102	117 Added 1.0%	11,816 $396,000
Q4 2023 Feb 23, 2024	BUY	$19.2 - $33.78 $83,078 - $146,166	4,327 Added 58.7%	11,699 $377,000
Q3 2023 May 17, 2024	BUY	$31.89 - $39.03 $26,628 - $32,590	835 Added 10.98%	8,442 $276,000
Q2 2023 May 17, 2024	SELL	$30.5 - $37.4 $124,806 - $153,040	-4,092 Reduced 34.98%	7,607 $267,000
Q1 2023 May 17, 2024	SELL	$30.8 - $53.92 $138,908 - $243,179	-4,510 Reduced 38.55%	7,189 $234,000
Q4 2022 Feb 10, 2023	SELL	$45.4 - $60.91 $12,575 - $16,872	-277 Reduced 3.62%	7,372 $406,000
Q3 2022 Nov 02, 2022	BUY	$42.06 - $55.45 $22,417 - $29,554	533 Added 7.49%	7,649 $453,000
Q2 2022 Jul 11, 2022	SELL	$33.54 - $52.15 $3,555 - $5,527	-106 Reduced 1.47%	7,116 $390,000
Q1 2022 Apr 12, 2022	BUY	$33.14 - $51.13 $239,337 - $369,260	7,222 New	7,222 $341,000

Others Institutions Holding HRMY

# of Institutions

255

Shares Held

46.7M

Call Options Held

119K

Put Options Held

50K

View Full List

About Harmony Biosciences Holdings, Inc.

Ticker HRMY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,161,400
Market Cap $2.09B
Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...

More about HRMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cim, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cim, LLC with notifications on news.

Account